PALO ALTO, Calif., May 27, 2010 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that Chief Financial Officer Rodney Young will present at two upcoming investor conferences taking place in New York City.
On Tuesday, June 1, Mr. Young will represent the Company at the Stem Cell Investor & Executive Networking Conference Event (S.C.I.E.N.C.E) hosted by National Securities and MD Becker Partners.
On Thursday, June 10, Mr. Young will present an update on the Company's programs and operations at the Jefferies & Company Global Life Sciences Conference. Mr. Young is scheduled to speak at 10:00 a.m. EDT with a 30-minute breakout session immediately after. A live webcast of this presentation will be available at http://www.wsw.com/webcast/jeff46/stem/ as well as through the Company's corporate website at http://www.stemcellsinc.com under the Investors section. Interested parties are encouraged to connect to the website at least 15 minutes prior to the presentation to ensure adequate time for any software downloads that may be necessary. A replay will also be accessible through the Company's website for 30 days following the event.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics and tools for use in stem cell-based research and drug discovery. In its cellular medicine programs, StemCells is developing therapeutic products targeting diseases of the central nervous system and liver. StemCells' lead product candidate, HuCNS-SC® cells (purified human neural stem cells), is in clinical development for the treatment of two fatal neurodegenerative disorders that primarily affect young children. StemCells also markets specialty cell culture products under the SC Proven® brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. The Company has exclusive rights to approximately 55 issued or allowed U.S. patents and over 200 granted or allowed non-U.S. patents. Further information about StemCells is available at www.stemcellsinc.com.
The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the clinical development of its HuCNS-SC cells; the Company's ability to commercialize drug discovery and drug development tools; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009 and in its subsequent reports on Form 10-Q and Form 8-K.